EVGN, IL0011050551

Evogene stock: Shareholders approve cooperation agreement

Published on 11/16/2026 at 02:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evogene stock now has a seven-member board after shareholders approved three proposals and a cooperation agreement. The agreement took effect on November 10.

Shareholder vote reshapes Evogene

  • Evogene shareholders approved a cooperation agreement with L.I.A. Pure Capital and Invest-Pro Shukai Hon.
  • The agreement took effect at the end of the November 10 special general meeting.
  • Evogene plans to release third-quarter 2026 results on November 19.
EVGN, IL0011050551, Illustration mit AI erstellt.

Evogene shareholders approved a cooperation agreement and three proposals at a special general meeting on November 10, 2026. The agreement with L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon. Ltd. became effective at the end of the meeting, according to the company's Form 6-K filing.

Agreement takes effect after vote

The filing said the shareholder vote covered Proposals Nos. 1-3 from the company's proxy materials. It also confirmed a seven-member board consisting of Nir Nimrodi, Leon Y. Recanati, Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok and President and CEO Ofer Haviv.

The vote gives effect to the cooperation arrangement after a period of shareholder disagreement. The filing did not disclose financial terms for the agreement.

Results due November 19

Evogene plans to release its third-quarter 2026 financial results on Thursday, November 19, followed by a management conference call at 9:00 a.m. Eastern time, or 4:00 p.m. Israel time. The schedule appears on the company's investor relations page.

Computational chemistry business

Evogene develops generative artificial intelligence for designing and optimizing small molecules. Its work covers pharmaceutical and agricultural applications, including computational chemistry programs intended to support drug and crop-related development. The company is headquartered in Rehovot, Israel, and its shares trade on Nasdaq and the Tel Aviv Stock Exchange.

Evogene at a glance

  • Company: Evogene Ltd.
  • ISIN: IL0011050551
  • Listings: Nasdaq and Tel Aviv Stock Exchange
  • Headquarters: Rehovot, Israel
  • Business: Generative AI and computational chemistry for pharmaceutical and agricultural applications

Israel's equity market is the broader setting for investors following Evogene, alongside the TA-35 market environment.

More news and analyses on Evogene stock.

Disclaimer...
en | IL0011050551 | EVGN | boerse | 70518564 | bgmi